UNRESECTABLE URETHRAL UROTHELIAL CARCINOMA
Clinical trials for UNRESECTABLE URETHRAL UROTHELIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE URETHRAL UROTHELIAL CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE URETHRAL UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to fight tough bladder cancer
Disease control OngoingThis study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced or spreading bladder cancer who cannot take standard cisplatin chemo. About 72 adults with recurrent or metastatic urothe…
Matched conditions: UNRESECTABLE URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a gene test tell who responds to immunotherapy for bladder cancer?
Knowledge-focused OngoingThis small phase II trial is studying whether specific gene mutations (ARID1A and KDM6A) and a protein called CXCL13 can predict how well patients with advanced bladder cancer respond to the immunotherapy drug nivolumab. Six participants with metastatic urothelial cancer whose tu…
Matched conditions: UNRESECTABLE URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC